The Italian National Health System (SSN) has pioneered a proactive remote monitoring model that replaces traditional "passive surveillance." In 2026, Italian patients on DOACs (like Apixaban or Edoxaban) are increasingly managed via AI-supported platforms.

These systems analyze real-time data to identify high-risk patterns—such as a subtle decline in glomerular filtration rate (renal function) or a drop in hemoglobin—long before physical symptoms appear. By shifting from scheduled check-ups to predictive alerts, Italian clinics have significantly reduced emergency hospitalizations for occult bleeding and stroke.